| Literature DB >> 27882237 |
Pavel Vašek1, Josef Krajnik2, David J Kopsky3, Vladimir Kalina4, Marek Frydrych5.
Abstract
Colorectal cancer is the third most common cancer. Approximately 20% of patients have at the time of presentation metastasized colorectal cancer, which is incurable in ~80% of cases. The present case report describes a typical case diagnosed with an advanced invasive colorectal adenocarcinoma, with two suspect hypodense lesions in the liver, as revealed by sonography. Judged inoperable for a curative outcome by radical resection, the patient was treated with a novel surgical technique based on stimulating the immune system, termed 'autologous tumor immunizing devascularization' (ATID). The tumor was isolated from its surroundings by ligature of arteries and veins, and subsequently the completely devascularized tumor was left in situ. The distal part of the rectum was closed, and a stoma was made from the proximal part of the colon. Following ATID, the stressing pathophysiological condition of the completely isolated tumor provoked a generalized cellular immune response, which led to the elimination of the devascularized tumor and distant lesions without causing sepsis. The patient did not experience any serious side-effects following the operation, and refused any adjuvant chemo- and/or radiotherapy. To date, the patient has no complaints and remains in good health after the ATID intervention, already more than 14 years. The present case study provides a typical demonstration of the clinical safety of ATID, and also indicates both the immunizing and the curative potential of the method.Entities:
Keywords: antigen; colon and rectum; colorectal neoplasms; immunotherapy; ligation; neoplasm; surgery specialty
Year: 2016 PMID: 27882237 PMCID: PMC5103851 DOI: 10.3892/mco.2016.1033
Source DB: PubMed Journal: Mol Clin Oncol ISSN: 2049-9450
Retrospective simulation of immunolysis.
| Primary tumor | Metastases | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sim. no. | Case | TDT days | DV cc | TI days | CL % | VM1 cc | TI days | CL % | VM2 cc | TI days | CL % | Rd |
| ( | CS | 30 | 220 | 80 | 50 | 1.5 | 40 | 80 | 0.5 | 30 | 90 | 110 |
| ( | CS | 14 | 220 | 80 | 50 | 1.5 | 50 | 75 | 0.5 | 30 | 83 | 110 |
| ( | CS | 10 | 220 | 80 | 50 | 1.5 | 60 | 75 | 0.5 | 50 | 81 | 110 |
| ( | CS | 7 | 220 | 80 | 50 | 1.5 | 75/R | 56 | 0.5 | 70 | 64 | 110 |
| ( | EC | 7 | 220 | 80 | 50 | 1.35 | 80/R | 52 | 0.65 | 90 | 45 | 110 |
| ( | EC | 7 | 220 | 80 | 50 | 1.25 | 90/R | 45 | 0.75 | 100 | 40 | 110 |
| ( | EC | 10 | 20 | 55 | 68 | 1.5 | 65 | 60 | 0.5 | 45 | 78 | 10 |
| ( | EC | 10 | 10 | 45 | 78 | 1.5 | 70 | 60 | 0.5 | 50 | 74 | 5 |
| ( | EC | 10 | 6 | 45 | 78 | 1.5 | 65 | 60 | 0.5 | 45 | 78 | 3 |
| ( | EC | 7 | 20 | 55 | 68 | 1.5 | 75/R | 56 | 0.5 | 75 | 60 | 10 |
Sim. no., simulation number; TDT, tumor volume-doubling time; DV, devascularized volume of tumor; TI, time of complete immunolysis or beginning of regrowth; CL, percentage of the maximum systemic concentration of cytotoxic lymphocytes following time TI; VM(1/2), volume of individual metastases 1 or 2; CS, case study; EC, exploratory calculation; Rd, ratio of devascularization [DV/(VM1 + VM2 + ……)]; R, regrowth.